SecBot SecBot
SECBOTREPLAY Home › Report › SYRE

SYRE · Spyre Therapeutics priced an underwritten public offering of 6.5…

Spyre Therapeutics, Inc. · PRESS-RELEASE filed Apr 14, 2026 at 22:38 ET

At the news

NEUTRALIMPACT 6/10

PRESS-RELEASE filed Apr 14, 2026 at 22:38 ET

Spyre Therapeutics priced an underwritten public offering of 6.5 million shares at $62.00 per share, raising approximately $403.0 million in gross proceeds, with an additional $60.5 million option for underwriters to purchase more shares. The offering is expected to close on April 16, 2026, subject to customary conditions.

  • Spyre Therapeutics is offering 6,500,000 shares of common stock at $62.00 per share.
  • Gross proceeds are expected to be approximately $403.0 million, before underwriting discounts and expenses.
  • Underwriters have a 30-day option to purchase up to an additional $60.5 million worth of shares.
  • The offering is expected to close on or about April 16, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access